Aclidinium Bromide Drug Utilisation Post-Authorisation Safety Studies (DUS): Common Protocol for Aclidinium (DUS1) and Aclidinium/Formoterol Fixed-Dose Combination (DUS2)

Trial Profile

Aclidinium Bromide Drug Utilisation Post-Authorisation Safety Studies (DUS): Common Protocol for Aclidinium (DUS1) and Aclidinium/Formoterol Fixed-Dose Combination (DUS2)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Aclidinium bromide/formoterol (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms DUS1/DUS2
  • Sponsors AstraZeneca
  • Most Recent Events

    • 08 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top